Evidence map›Paper›PMID 25247681›Full record

ArticleRedox report : communications in free radical research2015

Comparative analysis of antioxidative systems in malignant and benign brain tumours.

Vojislav Bogosavljević, Milica Bajčetić, Ivan Spasojević

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Redox report : communications in free radical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Vojislav Bogosavljević
Milica Bajčetić
Ivan Spasojević
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesComparison of redox conditions in malignant and benign tumours is essential for understanding the role of reactive oxygen species in the pathophysiology of aggressive cancer profiles. Here we compare antioxidative systems in highly malignant brain tumour - glioblastoma multiforme (GBM), and in meningioma, a benign brain tumour.

methodsTumour tissues and blood of 67 GBM patients (mean age: 52.9 ± 11.5 years) and 67 meningioma patients (59.2 ± 10.2 years), and blood of 30 control subjects (50.8 ± 12.8 years) were analysed via biochemical assays.

resultsComponents of glutathione system, which is responsible for H2O2 removal, showed lower activity/level in GBM: glutathione peroxidase (GBM: 9.90 ± 0.22; meningioma: 11.78 ± 0.23 U/mg of proteins; P < 0.001), glutathione reductase (GBM: 3.83 ± 0.13; meningioma: 4.67 ± 0.11 U/mg of proteins; P < 0.001), and glutathione (GBM: 6.70 ± 0.12; meningioma: 7.58 ± 0.14 μmol/g of tissue; P < 0.001). In contrast, the rank order of glutathione reductase activity and glutathione level in erythrocytes was: GBM > meningioma > control. Superoxide dismutase and catalase activities were lower in the blood of cancer patients compared to controls. DISCUSSION: Cells of malignant brain tumour show down-regulated antioxidative system which might result in increased levels of H2O2 compared to benign tumour tissue.

Indexed as

AdultAntioxidantsBrain NeoplasmsCase-Control StudiesCatalaseErythrocytesFemaleGlioblastomaGlutathioneGlutathione PeroxidaseGlutathione ReductaseHumansMaleMeningiomaMiddle AgedSuperoxide DismutaseAntioxidantsCatalaseGlutathioneGlutathione PeroxidaseGlutathione ReductaseSuperoxide DismutaseErythrocytesGlioblastomaGlutathione peroxidaseGlutathione reductaseHydrogen peroxideMeningioma

Identifiers

PMID25247681
PMCPMC6837427
OpenAlexW1993125031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.